Industry wary of new German pricing rule

Share this article:

Germany's a tough market for drugmakers, and in two months, the country's move to disclose discounted drug prices has pharmaceutical manufacturers worried about the impact this transparency will have on their ability to raise prices in other territories.

Reuters reports that the new law, which is set to go into effect in April, is intended to force pricing to be based on discounts, not wholesale prices, because the discounted prices, which Reuters says can be around 20%, will now be out in the open. Reuters says the concern is that some countries already use Germany's pricing as a benchmark, and this new peg would mean even lower prices in even more geographies should the math go live.

Jagen Pfundner, the chairman of Germany's pharma lobby VFA, and head of Swiss drugmaker Roche's German unit, told Reuters that drugmakers may keep certain drugs off the German market to avoid a watershed of discounts, but Reuters notes this would also mean opting out of the world's third-largest drug market.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.